Anixa Biosciences Plans AI-Driven Personalized Cancer Vaccines with VERDI Solutions

Anixa Biosciences has entered a letter of intent with VERDI Solutions to develop personalized and off-the-shelf cancer vaccines that leverage AI and cloud computing. This collaboration aims to initiate clinical trials in the U.S., following successful personalized treatment attempts in Europe under the Individueller Heilversuch framework. Concurrently, Anixa has received a Notice of Allowance from the USPTO for a patent on its ovarian cancer vaccine technology, which targets the Anti-Mullerian Hormone Receptor, Type II (AMHR2). The vaccine, developed with the Cleveland Clinic and the National Cancer Institute, focuses on high-risk populations, particularly those with BRCA mutations. Dr. Amit Kumar, CEO of Anixa, highlighted the patent's broad claims as a significant milestone in their efforts to advance cancer treatment. The company's ongoing projects also include a CAR-T therapy for recurrent ovarian cancer, further enhancing its research portfolio.